Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

PDCD1

4 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

The Use of TF-Ag-α to Selectively Capture Tumor-Derived Extracellular Vesicles and Enhance the Predictive Performance of Extracellular Vesicle PD-L1 for Response to Immune Checkpoint Inhibitors

Hsu CC, Qi M, Ito F, et al.

Cancer research communications

Assessing extracellular vesicle (EV) PD-L1 via liquid biopsy is an attractive non-invasive approach, but its predictive efficacy is confounded by non-tumor-derived EV background. To overcome this limitation, a novel assay selectively captured tumor-derived EVs (TEX) using the tumor-specific glycoantigen TF-Ag-α in serum from 91 NSCLC patients undergoing anti-PD-1 therapy. While baseline levels showed moderate performance (AUC 0.76), dynamic fold changes after the first treatment cycle revealed a ~4.18-fold increase in responders and a ~20% decrease in non-responders. This dynamic on-treatment metric delivered superior predictive power with an AUC of 0.93 (sensitivity 0.95, specificity 0.80), substantially outperforming both total EV PD-L1 and conventional tissue PD-L1.

Clinical · Molecular biology

Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype

Gantzer J, Lu X, Weingertner N, et al.

European journal of cancer (Oxford, England

This study performed integrated genomic, transcriptomic, and DNA methylation profiling on 76 desmoid tumors (DTs), uncovering frequent mutations in chromatin-remodeling genes, notably KMT2C, in addition to the known CTNNB1 and APC mutations. Transcriptomic analysis identified two robust molecular subtypes: immune-myogenic and mesenchymal-like. The immune-myogenic subtype exhibited high expression of myogenic markers and immune checkpoint genes, alongside enhancer hypomethylation. This subtype is associated with increased immune cell infiltration and predicts a higher responsiveness to immune checkpoint inhibitors.

Clinical

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies

Truntzer C, Thibaudin M, Bousquet PA, et al.

Oncoimmunology

This pooled analysis of two phase II clinical trials, MEDITREME and METIMMOX, investigated the efficacy of first-line chemoimmunotherapy in patients with microsatellite stable (MSS) metastatic colorectal cancer. The findings revealed a significant improvement in median overall survival for the chemoimmunotherapy group compared to chemotherapy alone. Additionally, higher complete response rates were observed with the combination therapy. The study also suggests that baseline CD8+ T-cell infiltration could serve as a predictive biomarker to identify patients most likely to benefit from this treatment approach.

Clinical

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer

Shitara K, Elimova E, Liu T, et al.

The New England journal of medicine

An open-label, phase 3 trial evaluated zanidatamab, a HER2-targeted bispecific antibody, with or without tislelizumab (anti-PD-1), combined with chemotherapy, as first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma. Patients were randomized to receive zanidatamab-tislelizumab-chemotherapy, zanidatamab-chemotherapy, or trastuzumab-chemotherapy. Both zanidatamab-tislelizumab-chemotherapy and zanidatamab-chemotherapy arms demonstrated significantly longer progression-free survival (median 12.4 months for both) compared to trastuzumab-chemotherapy (8.1 months). Overall survival was also longer with zanidatamab-tislelizumab-chemotherapy (26.4 months) than with trastuzumab-chemotherapy (19.2 months). Diarrhea was the most common grade 3 or higher adverse event.